I am contacting you today on behalf of everyone impacted by frontotemporal degeneration (FTD), to thank you for your support of the NAPA Reauthorization Act (H.R.619). Frontotemporal degeneration (FTD) is a terminal and incurable neurodegenerative disease affecting the frontal and temporal lobes and is one of the related dementias included in the National Alzheimer's Project. FTD impacts behavior, decision-making, personality, language, and/or movement, irreversibly changing a person’s ability to relate to others. It affects more than 60,000 people in the United States with an average life expectancy of 7 to 13 years. There are currently no treatments to slow the progression of the disease. Thanks to the work implemented through NAPA, attention to FTD and other related dementias is increasing but there is still much that needs to be done. When NAPA released the initial draft of the National Plan to Address Alzheimer's Disease in 2012 there were no treatments available to slow the progression of dementia of any kind. Now, the first treatments to slow the progress of Alzheimer's disease are available thanks to the momentum NAPA has generated. This momentum must continue to build until treatments are available for all forms of dementia included in the National Alzheimer's Project. By sponsoring the NAPA Reauthorization Act (H.R.619), you are helping to ensure that the momentum will continue. Please encourage your colleagues to join you in support of the NAPA Reauthorization Act (H.R.619) and help bring hope to those experiencing all types of dementia included in the National Alzheimer’s Project. Thank you. For more information on FTD or this campaign, contact AFTD at advocacy@theaftd.org or 866.507.7222.

I am reaching out today to thank you for your support of the NAPA Reauthorization Act (H.R.619) on behalf of those affected by frontotemporal degeneration (FTD). FTD is a devastating neurodegenerative disease that impacts behavior, decision-making, personality, language, and movement, drastically altering an individual's ability to connect with others. With no current treatments available to slow its progression, FTD affects over 60,000 individuals in the United States, with an average life expectancy of 7 to 13 years. Through the National Alzheimer's Project, attention to FTD and other related dementias is increasing, yet there is still much work to be done. As we aim to advance research and treatment options for all forms of dementia, including FTD, the NAPA Reauthorization Act (H.R.619) plays a critical role in sustaining this momentum. The initial draft of the National Plan to Address Alzheimer's Disease in 2012 marked a turning point in dementia research and treatment, leading to the availability of the first treatments to slow Alzheimer's disease progression. This progress must extend to address all forms of dementia covered by the National Alzheimer's Project. Scheduled to expire in 2025, the NAPA Reauthorization Act (H.R.619) is key to ensuring the continuation of this vital work. By supporting this legislation, you are bringing hope to those impacted by FTD and all forms of dementia under the National Alzheimer's Project. I urge you to rally your colleagues in backing the NAPA Reauthorization Act (H.R.619) and in fostering progress towards improved outcomes for individuals affected by FTD. Together, we can make a meaningful difference. For more details on FTD or to get engaged with this campaign, please reach out to AFTD at advocacy@theaftd.org or call 866.507.7222.

I am reaching out to you today on behalf of all individuals impacted by frontotemporal degeneration (FTD), to thank you for your support of the NAPA Reauthorization Act (H.R.619). Frontotemporal degeneration (FTD) is a devastating neurodegenerative disease affecting the frontal and temporal lobes, recognized as one of the related dementias covered by the National Alzheimer's Project. FTD alters behavior, decision-making, personality, language, and/or movement, profoundly affecting a person’s ability to connect with others. With over 60,000 individuals in the United States affected by FTD and an average life expectancy of 7 to 13 years, the urgency to find effective interventions is crucial. Sadly, there are currently no treatments available to slow the progression of this disease. While progress has been made in increasing awareness and research through NAPA, there is still a significant distance to go. When the first draft of the National Plan to Address Alzheimer's Disease was released in 2012, no treatments were available to slow dementia progression. Now, due to the initiatives derived from NAPA, the first treatments to slow Alzheimer's disease are available. This positive shift needs to continue until treatments are developed for all forms of dementia recognized in the National Alzheimer's Project. NAPA is scheduled to end in 2025. By supporting the NAPA Reauthorization Act (H.R.619), you are playing a vital role in ensuring that this critical momentum endures. I urge you to rally your colleagues in endorsing the NAPA Reauthorization Act (H.R.619) and in providing hope to those facing all forms of dementia included in the National Alzheimer’s Project. Thank you. For further information on FTD or this campaign, please reach out to AFTD at advocacy@theaftd.org or 866.507.7222.

I am contacting you today on behalf of everyone impacted by frontotemporal degeneration (FTD), to urge you to support the NAPA Reauthorization Act (H.R.619). Frontotemporal degeneration (FTD) is a terminal and incurable neurodegenerative disease affecting the frontal and temporal lobes and is one of the related dementias included in the National Alzheimer's Project. FTD impacts behavior, decision-making, personality, language, and/or movement, irreversibly changing a person’s ability to relate to others. It affects more than 60,000 people in the United States with an average life expectancy of 7 to 13 years. There are currently no treatments to slow the progression of the disease. Thanks to the work implemented through NAPA, attention to FTD and other related dementias is increasing but there is still much that needs to be done. When NAPA released the initial draft of the National Plan to Address Alzheimer's Disease in 2012 there were no treatments available to slow the progression of dementia of any kind. Now, the first treatments to slow the progress of Alzheimer's disease are available thanks to the momentum NAPA has generated. This momentum must continue to build until treatments are available for all forms of dementia included in the National Alzheimer's Project. NAPA is set to expire in 2025. By supporting the NAPA Reauthorization Act (H.R.619), you can bring hope that these advances will be expanded to FTD, and all forms of dementia included in NAPA. Thank you. For more information on FTD or this campaign, contact AFTD at advocacy@theaftd.org or 866.507.7222.